Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant

References

• Centers for Disease Control and Prevention (CDC). Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep 2009;58:467–470.
   PubMedGoogle Scholar
• Smith GJ, Vijaykrishna D, Bahl J, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009;459:1122–1125.
   PubMed Web of Science ®Google Scholar
• New influenza A (H1N1) virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec 2009;84:249–257.
   PubMedGoogle Scholar
• Campbell A, Rodin R, Kropp R, et al. Risk of severe outcomes among patients admitted to hospital with pandemic (H1N1) influenza. CMAJ 2010;182:349–355.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pandemic (H1N1) 2009 - Update 69. 2009. Available from:http://www.who.int/csr/don/2009_10_09/en/index.html
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Update on influenza A (H1N1) 2009 monovalent vaccines. MMWR Morb Mortal Wkly Rep 2009;58:1100–1101.
   PubMedGoogle Scholar
• Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009;361:2405–2413.
   PubMed Web of Science ®Google Scholar
• Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009;361:2424–2435.
   PubMed Web of Science ®Google Scholar
• Product Information Leaflet Arepanrix™ H1N1 AS03-Adjuvanted H1N1 Pandemic Influenza Vaccine Version 2, approved 29 January 2010. Ottawa: Health Canada; 2009.
   Google Scholar
• World Health Organization. World Health Organization manual on animal influenza diagnosis and surveillance. Global Influenza Programme. Geneva: WHO; 2002.
   Google Scholar
• European Agency for the Evaluation of Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines. EMEA. Committee for Proprietary Medicinal Products. London, 12 March 1997.
   Google Scholar
• European Agency for the Evaluation of Medicinal Products. Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context. EMEA. Committee for Human Medicinal Products. London, 24 January 2007.
   Google Scholar
• US Food and Drug Administration. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. FDA. Center for Biologics Evaluation and Research. May 2007.
   Google Scholar
• Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979;35:69–75.
   PubMed Web of Science ®Google Scholar
• Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010;375: 56–66.
   PubMed Web of Science ®Google Scholar
• Plennevaux E, Sheldon E, Blatter M, et al. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010;375:41–48.
   PubMed Web of Science ®Google Scholar
• Roman F, Vaman T, Gerlach B, et al. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010;28:1740–1745.
   PubMed Web of Science ®Google Scholar
• Vajo Z, Tamas F, Sinka L, et al. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010;375:49–55.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009;361:2414–2423.
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Garland P, Sekine T, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 2012;96:307–314.
   Web of Science ®Google Scholar
• Engelhard D, Zakay-Rones Z, Shapira MY, et al. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic. Vaccine 2011;29:1777–1782.
   PubMed Web of Science ®Google Scholar
• Hottinger AF, George AC, Bel M, et al. A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients. Oncologist 2012;17:436–445.
   PubMed Web of Science ®Google Scholar
• Issa NC, Marty FM, Gagne LS, et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011;17:434–438.
   PubMed Web of Science ®Google Scholar
• Mariotti J, Spina F, Carniti C, et al. Long-term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies. Eur J Haematol 2012;89:111–119.
   PubMed Web of Science ®Google Scholar
• Brydak LB, Machala M, Centkowski P, et al. Humoral response to hemagglutinin components of influenza vaccine in patients with non-Hodgkin malignant lymphoma. Vaccine 2006;24:6620–6623.
   PubMed Web of Science ®Google Scholar
• Mazza JJ, Yale SH, Arrowood JR, et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res 2005;3:214–220.
   PubMedGoogle Scholar
• Avetisyan G, Aschan J, Hassan M, et al. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation 2008;86:257–263.
   PubMed Web of Science ®Google Scholar
• Engelhard D, Nagler A, Hardan I, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 1993;11: 1–5.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Avetisyan G. Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant 2008;42:637–641.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol 2005;130:96–98.
   PubMed Web of Science ®Google Scholar
• van der Velden AM, Mulder AH, Hartkamp A, et al. Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients. Eur J Intern Med 2001;12:420–424.
   PubMedGoogle Scholar
• Lo W, Whimbey E, Elting L, et al. Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. Eur J Clin Microbiol Infect Dis 1993;12:778–782.
   PubMed Web of Science ®Google Scholar
• Beck MA. Influenza and obesity: will vaccines and antivirals protect?J Infect Dis 2012;205:172–173.
   PubMed Web of Science ®Google Scholar
• Talbot HK, Coleman LA, Crimin K, et al. Association between obesity and vulnerability and serologic response to influenza vaccination in older adults. Vaccine 2012;30:3937–3943.
   PubMed Web of Science ®Google Scholar
• Yri OE, Torfoss D, Hugnes O, et al. Lymphoma patients treated with rituximab-containing regimens do not achieve protective serological responses to H1N1 influenza virus after vaccination. Ann Oncol 2011;22(Suppl. 4):iv131.
   Google Scholar
• Takata T, Suzumiya J, Ishikawa T, et al. Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. J Clin Exp Hematop 2009;49:9–13.
   PubMedGoogle Scholar
• Eriksson JC, Cox RJ, Szyszko E, et al. Local and systemic cytokine and chemokine responses after parenteral influenza vaccination. Influenza Other Respi Viruses 2007;1:139–146.
   PubMed Web of Science ®Google Scholar
• Shahid Z, Kleppinger A, Gentleman B, et al. Clinical and immunologic predictors of influenza illness among vaccinated older adults. Vaccine 2010;28:6145–6151.
   PubMed Web of Science ®Google Scholar
• Bermejo-Martin JF, Ortiz de Lejarazu R, Pumarola T, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care 2009;13:R201.
   PubMed Web of Science ®Google Scholar
• Pauksen K, Sjolin J, Linde A, et al. Th1 and Th2 cytokine responses after measles antigen stimulation in vitro in bone marrow transplant patients: response to measles vaccination. Bone Marrow Transplant 1997;20:317–323.
   PubMed Web of Science ®Google Scholar
• Dearing S. H1N1 vaccine safety becomes an issue in Canada. Digital Journal 23 October 2009; Sect. Article #280927.
   Google Scholar
• Weeks C. Low H1N1 vaccination rate alarms health experts. The Globe and Mail 28 May 2010; Sect. Article #1583841.
   Google Scholar